Commercial Novo Nordisk to launch Ozempic for type 2 diabetes in US Pharmaceutical TechnologyNovo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US.Metabolic & GLP-1Read full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaceutical Technology Novo Nordisk is set to launch Ozempic, its oral GLP-1 receptor agonist pill for adults with type 2 diabetes, in the US. Metabolic & GLP-1 Read full story Post navigation Previous: Pfizer, Arvinas join SERD club with Veppanu approvalNext: UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026